Search

H Lundbeck A-S

Open

42.92 0.52

Overview

Share price change

24h

Current

Min

42.9

Max

43

Key metrics

By Trading Economics

Income

665M

1.6B

Sales

256M

6.3B

P/E

Sector Avg

11.234

88.032

EPS

1.44

Dividend yield

2.21

Profit margin

25.975

Employees

5,700

EBITDA

1.6B

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.21%

2.26%

Market Stats

By TradingEconomics

Market Cap

-3.7B

41B

Previous open

42.4

Previous close

42.92

H Lundbeck A-S Chart

Past performance is not a reliable indicator of future results.

Related News

31 Dec 2025, 22:20 UTC

Major Market Movers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 Dec 2025, 17:31 UTC

Major Market Movers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 Dec 2025, 16:30 UTC

Major Market Movers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 Dec 2025, 15:19 UTC

Major Market Movers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 Dec 2025, 15:17 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 Dec 2025, 14:37 UTC

Major Market Movers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 Dec 2025, 21:13 UTC

Acquisitions, Mergers, Takeovers

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 Dec 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 Dec 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 Dec 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 Dec 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31 Dec 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31 Dec 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 Dec 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 Dec 2025, 17:16 UTC

Major Market Movers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 Dec 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31 Dec 2025, 17:00 UTC

Acquisitions, Mergers, Takeovers

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 Dec 2025, 15:57 UTC

Acquisitions, Mergers, Takeovers

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 Dec 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 Dec 2025, 15:02 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 Dec 2025, 14:40 UTC

Acquisitions, Mergers, Takeovers

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 Dec 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31 Dec 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 Dec 2025, 13:01 UTC

Earnings
Acquisitions, Mergers, Takeovers

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 Dec 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 Dec 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31 Dec 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 Dec 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 Dec 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

H Lundbeck A-S Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
help-icon Live chat